Lorlatinib is the third generation "ROS1 / ALK mutations in lung cancer targeted drugs.Carry ALK or ROS1 mutations in lung cancer patients are referred to as the "lucky" in lung cancer, because some of ALK or ROS1 mutations targeting drug curative effect is good, not only and more choice.For Laura's (Lorlatinib) was developed by Pfizer, a new type of small molecules, reversible and potent ALK and ROS1 inhibitors, its drug resistance mutation of ALK known all has a strong inhibitory effect, and therefore is known as the third generation of ALK inhibitors.
Indications: for the patients with tumor
Specification: 25 mg * 30 grains
Retail price: $500
Note: Lorlatinib is the third generation "ROS1 / ALK mutations in lung cancer targeted drugs.